STOCK TITAN

Vigil Neuroscience to Present at Stifel 2023 CNS Days

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Vigil Neuroscience (Nasdaq: VIGL) announced that Ivana Magovčević-Liebisch, Ph.D., J.D., its CEO, will participate in a fireside chat at the Stifel 2023 CNS Days virtual conference on March 29, 2023, at 12:00 p.m. ET. Investors can access the live webcast through the 'Events & Presentations' section on the company's website, with an archived replay available for 90 days post-event.

The company focuses on developing treatments for neurodegenerative diseases using microglia. Its lead candidate, VGL101, is in a Phase 2 trial for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), and it is also exploring treatments for Alzheimer's disease.

Positive
  • None.
Negative
  • None.

WATERTOWN, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2023 CNS Days virtual conference on Wednesday, March 29, 2023, at 12:00 p.m. ET.

To access a live webcast of this presentation, please visit “Events & Presentations” in the “Investors” section of the Vigil website at www.vigilneuro.com. An archived replay will be available for approximately 90 days following the presentation.

About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families. VGL101, our lead candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. We are also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the 'Investors' section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.


FAQ

What is the date and time of Vigil Neuroscience's presentation at the Stifel 2023 CNS Days conference?

Vigil Neuroscience will present on March 29, 2023, at 12:00 p.m. ET.

Where can I watch the Vigil Neuroscience presentation live?

The live webcast can be accessed in the 'Events & Presentations' section of Vigil Neuroscience's website.

What is Vigil Neuroscience's lead candidate for neurodegenerative diseases?

Vigil Neuroscience's lead candidate is VGL101, targeting adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

How long will the archived replay of the Vigil Neuroscience presentation be available?

The archived replay will be available for approximately 90 days after the presentation.

What is the focus of Vigil Neuroscience's research?

Vigil Neuroscience focuses on developing treatments for neurodegenerative diseases by restoring microglial function.

Vigil Neuroscience, Inc.

NASDAQ:VIGL

VIGL Rankings

VIGL Latest News

VIGL Stock Data

132.28M
32.00M
21.27%
80.16%
1.29%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WATERTOWN